A growing body of evidence has shown that aberrant activation/sequestration of signaling pathways such as PI3K/Akt [15–17], MAPK [18, 19], and TP53 [20, 21] is correlated with the inhibition of apoptosis that is often observed in cancers with acquired resistance to treatment [16, 22, 23], [24, 25]. The gene discussed is AKT1; the disease is cancer.